CLINICAL OUTCOMES AND ADHERENCE AMONG NSCLC PATIENTS USING PEMETREED AS FIRST-LINE TREATMENT BEFORE AND AFTER CRITICAL DISEASE INSURANCE (CDI) POLICY IMPLEMENTATION

Author(s)

Zhou JY1, Xie CY2, Li YP2, Yuan Y3, Xia B4, Wang LM5, Wang K3, Ma X6, Yao LD6, Zhan LJ6, Wang Y7, Ma SL5
1The first affiliated hospital,Zhejiang University, Hangzhou, China, 2The first provincial Wenzhou hospital of Zhejiang. Wenzhou, Wen Zhou, China, 3The second affiliated hospital, Zhejiang University School of Medicine, Hang Zhou, China, 4Hangzhou cancer hospital, Hang Zhou, China, 5Hangzhou first people’s hospital., Hang Zhou, China, 6Lilly Suzhou Pharmaceutical Co., Ltd Shanghai Branch, Shang Hai, China, 7Medbanks company, Beijing, China

OBJECTIVES:To evaluate the progression-free survival and its associated factors among non-squamous NSCLC patients with first-line pemetrexed therapy before and after CDI policy implementation in Zhejiang province.

METHODS: A total of 353 Zhejiang residents, who were diagnosed with stage IIIb/IV non-squamous NSCLC, initiating their first-line pemetrexed therapy between 1/1/2010 and 31/10/2016, were included. All subjects were followed till 7/18/2018. CDI status were described as before CDI (before 12/2014) and after CDI (01/2015-11/2016). Pemetrexed adherence was measured by treatment cycles and used >4 cycles as the cut-off point. Survival analyses were used to assess factors associated with PFS.

RESULTS: Percentage of patients with pemetrexed treatment >4 cycles was significantly higher (p<0.0001) after CDI (39.08 %) compared to before CDI implementation (17.39%). The median PFS of the entire study population was 9.4 months (95%CI: 8.6-12.7). The median PFS of the entire study population did not differ significantly between patients before CDI (median: 8.6 months, 95%CI: 6.8-11.8) and after CDI (median: 10.8 months, 95%CI: 8.7-14.6) (HR: 0.827, p=0.2281). Among patients who used CDI-covered pemetrexed, the median PFS of those before CDI and after CDI was 8.7 months (95%CI: 6.4-12.7) and 14.2 months (95%CI: 9.4-20.7) respectively. There was no significant difference between two groups (HR: 0.759, p=0.2124). The median PFS among patients with pemetrexed treatment >4 cycles (median: 14.6 months, 95%CI: 10.8-35.7) was significantly longer than the PFS among patients with pemetrexed treatment ≤4 cycles (median: 7.2 months, 95%CI: 5.1-9.2) (HR: 0.464, p<0.0001). Multivariate Cox regression analysis showed a statistically significant association only between pemetrexed adherence and PFS (HR: 0.488, p<0.0179)

CONCLUSIONS:Zhejiang CDI policy has a positive impact on improving the pemetrexed adherence for advanced non-squamous NSCLC patients. While better pemetrexed adherence (treatment cycles >4 cycles) is significantly associated with longer PFS, the direct association between CDI policy implementation and PFS is inconclusive.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCN191

Topic

Clinical Outcomes, Economic Evaluation, Health Policy & Regulatory, Real World Data & Information Systems

Topic Subcategory

Clinical Outcomes Assessment, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Health & Insurance Records Systems, Pricing Policy & Schemes

Disease

Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×